{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T14:39:51Z","timestamp":1772635191092,"version":"3.50.1"},"reference-count":108,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Geriatric Pharmacotherapy"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.amjopharm.2009.12.002","type":"journal-article","created":{"date-parts":[[2010,1,26]],"date-time":"2010-01-26T05:11:53Z","timestamp":1264482713000},"page":"324-342","source":"Crossref","is-referenced-by-count":59,"title":["Pharmacologic management of the older patient with type 2 diabetes mellitus"],"prefix":"10.1016","volume":"7","author":[{"given":"Joshua J.","family":"Neumiller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Setter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjopharm.2009.12.002_bib1","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.mcna.2004.04.013","article-title":"Pathogenesis of type 2 diabetes mellitus","volume":"88","author":"DeFronzo","year":"2004","journal-title":"Med Clin North Am."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1742-1241.2007.01437.x","article-title":"Antihyperglycaemic therapy in elderly patients with type 2 diabetes: Potential role of incretin mimetics and DPP-4 inhibitors","volume":"61","author":"Mathieu","year":"2007","journal-title":"Int J Clin Pract Suppl."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib5","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.299.16.1929","article-title":"Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs","volume":"299","author":"Hsu","year":"2008","journal-title":"JAMA."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib6","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1001\/jama.299.16.1922","article-title":"Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D","volume":"299","author":"Madden","year":"2008","journal-title":"JAMA."},{"issue":"Suppl 1","key":"10.1016\/j.amjopharm.2009.12.002_bib7","first-page":"S13","article-title":"Standards of medical care in diabetes\u20142009","volume":"32","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib8","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet. 1998;352:1558]","volume":"352","year":"1998","journal-title":"Lancet."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","year":"1993","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy [published correction appears in Lancet. 2000;356:860]","volume":"355","year":"2000","journal-title":"Lancet."},{"issue":"Suppl 5","key":"10.1016\/j.amjopharm.2009.12.002_bib11","first-page":"S265","article-title":"Guidelines for improving the care of the older person with diabetes mellitus","volume":"51","author":"Brown","year":"2003","journal-title":"J Am Geriatr Soc."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib12","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2337\/diacare.20.4.614","article-title":"Cholesterol lowering with simvastatin improves prognosis of diabeticpatients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) [published correction appears in Diabetes Care. 1997; 20:1048]","volume":"20","author":"Py\u00f6r\u00e4l\u00e4","year":"1997","journal-title":"Diabetes Care."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib13","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1001\/jama.1996.03540230036032","article-title":"Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension [published correction appears in JAMA. 1997;277:1356]","volume":"276","author":"Curb","year":"1996","journal-title":"JAMA."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib14","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-Year followup of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib15","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib16","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib17","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1532-5415.1985.tb07117.x","article-title":"Longitudinal studies on the rate of decline in renal function with age","volume":"33","author":"Lindeman","year":"1985","journal-title":"J Am Geriatr Soc."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib18","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1136\/bmj.3.5775.607","article-title":"Effect of age and sex on human drug metabolism","volume":"3","author":"O\u2019Malley","year":"1971","journal-title":"Br Med J."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib20","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.exger.2004.05.011","article-title":"Drug therapy in the elderly","volume":"39","author":"Turnheim","year":"2004","journal-title":"Exp Gerontol."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00003088-199121030-00002","article-title":"Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part I)","volume":"21","author":"Greenblatt","year":"1991","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib22","first-page":"6","article-title":"Determination of body composition by multiisotope method and the elimination kinetics of these isotopes in healthy elderly subjects","volume":"31","author":"F\u00fcl\u00f6p","year":"1985","journal-title":"Gerontology."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2165\/00002512-199813050-00003","article-title":"Drug dosage in the elderly. Is it rational?","volume":"13","author":"Turnheim","year":"1998","journal-title":"Drugs Aging."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib24","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1001\/archinte.163.22.2716","article-title":"Updating the Beers criteria for potentially inappropriate medication use in older adults: Results of a US consensus panel of experts [published correction appears in Arch Intern Med. 2004;164:298]","volume":"163","author":"Fick","year":"2003","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib25","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00002512-199915060-00007","article-title":"The use of sulphonylureas in the elderly","volume":"15","author":"Graal","year":"1999","journal-title":"Drugs Aging."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib26","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/01.mjt.0000183719.84390.4d","article-title":"Pharmacokinetic-pharmacodynamic crisis in the elderly","volume":"14","author":"ElDesoky","year":"2007","journal-title":"Am J Ther."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2165\/00002512-200522030-00003","article-title":"Management of diabetes mellitus medications in the nursing home","volume":"22","author":"Haas","year":"2005","journal-title":"Drugs Aging."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib28","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2165\/00002512-200724100-00005","article-title":"Individualising therapy for older adults with diabetes mellitus","volume":"24","author":"Cayea","year":"2007","journal-title":"Drugs Aging."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib29","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1016\/S0149-2918(03)90089-0","article-title":"Metformin hydrochloride in the treatment of type 2 diabetes mellitus: A clinical review with a focus on dual therapy","volume":"25","author":"Setter","year":"2003","journal-title":"Clin Ther."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-137-1-200207020-00009","article-title":"Metformin: An update","volume":"137","author":"Kirpichnikov","year":"2002","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib31","series-title":"Glucophage\/Glucophage XR [package insert]","year":"2009"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib32","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.2337\/diacare.21.10.1659","article-title":"Lactic acidosis rates in type 2 diabetes [published correction appears in Diabetes Care. 1998;21:2203]","volume":"21","author":"Brown","year":"1998","journal-title":"Diabetes Care."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib33","doi-asserted-by":"crossref","first-page":"386","DOI":"10.7326\/0003-4819-147-6-200709180-00178","article-title":"Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus [published correction appears in Ann Intern Med. 2007;147:887]","volume":"147","author":"Bolen","year":"2007","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib34","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0895-4356(97)00024-3","article-title":"Rates of hypoglycemia in users of sulfonylureas","volume":"50","author":"van Staa","year":"1997","journal-title":"J Clin Epidemiol."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3949\/ccjm.75.1.70","article-title":"Managing diabetes in the elderly: Go easy, individualize","volume":"75","author":"Hornick","year":"2008","journal-title":"Cleve Clin J Med."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2165\/00002512-200421080-00003","article-title":"Hypoglycemia in elderly patients with diabetes mellitus: Causes and strategies for prevention","volume":"21","author":"Chelliah","year":"2004","journal-title":"Drugs Aging."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib37","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/dmrr.235","article-title":"Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide","volume":"17","author":"Holstein","year":"2001","journal-title":"Diabetes Metab Res Rev."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib38","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib39","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.27.1.256","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association","volume":"27","author":"Nesto","year":"2004","journal-title":"Diabetes Care."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib40","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.287.3.360","article-title":"Oral antihyperglycemic therapy for type 2 diabetes: Scientific review","volume":"287","author":"Inzucchi","year":"2002","journal-title":"JAMA."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib42","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2337\/dc07-2270","article-title":"Rosiglitazone-associated fractures in type 2 diabetes: An Analysis from A Diabetes Outcome Progression Trial (ADOPT)","volume":"31","author":"Kahn","year":"2008","journal-title":"Diabetes Care."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib43","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archinte.168.8.820","article-title":"Use of thiazolidinediones and fracture risk","volume":"168","author":"Meier","year":"2008","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1517\/14740338.7.1.69","article-title":"Effect of thiazolidinediones on skeletal health in women with Type 2 diabetes","volume":"7","author":"Schwartz","year":"2008","journal-title":"Expert Opin Drug Saf."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib45","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1001\/jama.298.10.1189","article-title":"Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis","volume":"298","author":"Singh","year":"2007","journal-title":"JAMA."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib46","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in N Engl J Med. 2007;357:100]","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib47","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib48","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomized, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib49","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1001\/jama.298.22.2634","article-title":"Thiazolidinediones and cardiovascular outcomes in older patients with diabetes","volume":"298","author":"Lipscombe","year":"2007","journal-title":"JAMA."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib50","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1001\/archinte.168.21.2368","article-title":"Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy","volume":"168","author":"Winkelmayer","year":"2008","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1345\/aph.1H459","article-title":"Rationale for dipeptidyl peptidase 4 inhibitors: A new class of oral agents for the treatment of type 2 diabetes mellitus","volume":"41","author":"Campbell","year":"2007","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib52","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1742-1241.2006.01178.x","article-title":"DPP-4 inhibitors and their potential role in the management of type 2 diabetes","volume":"60","author":"Barnett","year":"2006","journal-title":"Int J Clin Pract."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib54","series-title":"Januvia [package insert]","year":"2009"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib55","series-title":"WelChol [package insert]","year":"2009"},{"issue":"Suppl 1","key":"10.1016\/j.amjopharm.2009.12.002_bib56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3810\/pgm.2009.05.suppl53.290","article-title":"A review of bile acid sequestrants: Potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitus","volume":"121","author":"Staels","year":"2009","journal-title":"Postgrad Med."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib57","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2165\/00003495-200767100-00001","article-title":"Bile acid sequestrants and the treatment of type 2 diabetes mellitus","volume":"67","author":"Staels","year":"2007","journal-title":"Drugs."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib58","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.clinthera.2007.01.003","article-title":"Results of the Glucose-Lowering Effect of WelChol Study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes","volume":"29","author":"Zieve","year":"2007","journal-title":"Clin Ther."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib59","first-page":"733","article-title":"Colesevelam hydrochloride: Reducing atherosclerotic coronary heart disease risk factors","volume":"3","author":"Bays","year":"2007","journal-title":"Vasc Health Risk Manag."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib60","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1517\/14656566.8.15.2593","article-title":"Exenatide","volume":"8","author":"Barnett","year":"2007","journal-title":"Expert Opin Pharmacother."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib61","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1177\/0145721706294003","article-title":"Update in the pharmacologic treatment of diabetes mellitus: Focus on pramlintide and exenatide","volume":"32","author":"Odegard","year":"2006","journal-title":"Diabetes Educ."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib62","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib63","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib64","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib65","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2125.2007.02890.x","article-title":"Effect of renal impairment on the pharmacokinetics of exenatide","volume":"64","author":"Linnebjerg","year":"2007","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib66","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2337\/diaspect.20.4.239","article-title":"Considerations for the pharmacological treatment of diabetes in older adults","volume":"20","author":"Odegard","year":"2007","journal-title":"Diabetes Spectrum."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib67","series-title":"Byetta injection [package insert]","year":"2009"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib68","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-146-7-200704030-00003","article-title":"The effect of adding exenatide to thiazolidinedione in suboptimally controlled type 2 diabetes: A randomized trial [published correction appears in Ann Intern Med. 2007;146:896]","volume":"146","author":"Zinman","year":"2007","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib70","series-title":"Symlin injection [package insert]","year":"2008"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib71","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1055\/s-2007-978777","article-title":"The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus","volume":"31","author":"Borm","year":"1999","journal-title":"Horm Metab Res."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib72","series-title":"Omnicare Geriatric Pharmaceutical Care Guidelines","first-page":"349","article-title":"Diabetes mellitus","year":"2009"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib73","series-title":"Amaryl tablets [package insert]","year":"2005"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib74","series-title":"Glucotrol [package insert]","year":"2000"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib75","series-title":"Diabeta [package insert]","year":"2009"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib76","series-title":"Prandin [package insert]","year":"2006"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib77","series-title":"Starlix [package insert]","year":"2008"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib78","series-title":"Actos [package insert]","year":"2009"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib79","series-title":"Avandia [package insert]","year":"2008"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib80","series-title":"Onglyza [package insert]","year":"2009"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib81","series-title":"Precose [package insert]","year":"2008"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib82","series-title":"Glyset tablets [package insert]","year":"2008"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib83","doi-asserted-by":"crossref","first-page":"755","DOI":"10.7326\/0003-4819-147-11-200712040-00006","article-title":"Medication use leading to emergency department visits for adverse drug events in older adults","volume":"147","author":"Budnitz","year":"2007","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib84","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00002512-200118010-00003","article-title":"Management of type 2 diabetes mellitus in the elderly: Special considerations","volume":"18","author":"Rosenstock","year":"2001","journal-title":"Drugs Aging."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib85","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.diabet.2009.02.003","article-title":"A call to incorporate the prevention and treatment of geriatric disorders in the management of diabetes in the elderly","volume":"35","author":"Vischer","year":"2009","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib86","series-title":"Humalog [package insert]","year":"2009"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib87","series-title":"NovoLog [package insert]","year":"2009"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib88","series-title":"Apidra [package insert]","year":"2009"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib89","series-title":"Humulin R [package insert]","year":"2007"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib90","series-title":"Novolin R Innolet [package insert]","year":"2003"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib91","series-title":"Humulin N [package insert]","year":"2009"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib92","series-title":"Novolin N Innolet [package insert]","year":"2004"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib93","series-title":"Lantus [package insert]","year":"2007"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib94","series-title":"Levemir [package insert]","year":"2009"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib95","series-title":"Humulin 70\/30 [package insert]","year":"2007"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib96","series-title":"Novolin 70\/30 Innolet [package insert]","year":"2004"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib97","series-title":"Humulin 50\/50 [package insert]","year":"2007"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib98","series-title":"NovoLog Mix 70\/30 [package insert]","year":"2009"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib99","series-title":"Humalog Mix75\/25 [package insert]","year":"2009"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib100","series-title":"Humalog Mix50\/50 [package insert]","year":"2009"},{"key":"10.1016\/j.amjopharm.2009.12.002_bib101","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0168-8227(95)01092-R","article-title":"Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old","volume":"28","author":"Coscelli","year":"1995","journal-title":"Diabetes Res Clin Pract."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib102","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib103","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1532-5415.2007.01043.x","article-title":"Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus","volume":"55","author":"Janka","year":"2007","journal-title":"J Am Geriatr Soc."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib104","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2337\/diacare.24.4.631","article-title":"Basal insulin therapy in type 2 diabetes: 28-Week comparison of insulin glargine (HOE 901) and NPH insulin","volume":"24","author":"Rosenstock","year":"2001","journal-title":"Diabetes Care."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib105","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2337\/dc05-1365","article-title":"A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes [published correction appears in Diabetes Care. 2007;30:1035]","volume":"29","author":"Hermansen","year":"2006","journal-title":"Diabetes Care."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib106","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.clinthera.2006.10.020","article-title":"Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes [published correction appears in Clin Ther. 2006;28:1967]","volume":"28","author":"Philis-Tsimikas","year":"2006","journal-title":"Clin Ther."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib107","doi-asserted-by":"crossref","first-page":"125","DOI":"10.7326\/0003-4819-145-2-200607180-00010","article-title":"Narrative review: A rational approach to starting insulin therapy","volume":"145","author":"Mooradian","year":"2006","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib108","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jamda.2006.01.002","article-title":"The application of evidence-based principles of care in older persons (issue 3): Management of diabetes mellitus","volume":"7","author":"Zarowitz","year":"2006","journal-title":"J Am Med Dir Assoc."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib109","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.2337\/diacare.15.11.1628","article-title":"Use of premixed insulin among the elderly. Reduction of errors in patient preparation of mixtures","volume":"15","author":"Coscelli","year":"1992","journal-title":"Diabetes Care."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib110","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.clinthera.2005.07.003","article-title":"Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues","volume":"27","author":"Rolla","year":"2005","journal-title":"Clin Ther."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib111","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2337\/diacare.28.2.260","article-title":"Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs","volume":"28","author":"Raskin","year":"2005","journal-title":"Diabetes Care."},{"issue":"Suppl 3","key":"10.1016\/j.amjopharm.2009.12.002_bib112","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.ijo.0802173","article-title":"When oral agents fail: Practical barriers to starting insulin","volume":"26","author":"Korytkowski","year":"2002","journal-title":"Int J Obes Relat Metab Disord."},{"key":"10.1016\/j.amjopharm.2009.12.002_bib113","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0168-8227(01)00327-8","article-title":"Insulin improves well-being for selected elderly type 2 diabetic subjects","volume":"55","author":"Reza","year":"2002","journal-title":"Diabetes Res Clin Pract."}],"container-title":["The American Journal of Geriatric Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594609000877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594609000877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T14:20:00Z","timestamp":1544710800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1543594609000877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":108,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S1543594609000877"],"URL":"https:\/\/doi.org\/10.1016\/j.amjopharm.2009.12.002","relation":{},"ISSN":["1543-5946"],"issn-type":[{"value":"1543-5946","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}